Finally, current guidelines recommend routine evaluation of ER (estrogen receptor), PgR (progesterone receptor), and HER2 (human epidermal growth factor receptor 2) status in all patients with invasive BC, recurrences, and metastases [6,7]. Here, ESR1 is linked to breast cancer.